연구동향 분석
박사

Neuroimaging studies for schizophrenia: Brain functional abnormality : Abnormal serotonin transporter binding, glucose metabolism, and interregional correlation in schizophrenia: A dual tracer PET study with 11C-DASB and 18F-FDG

김정희 2015년

논문상세정보
인용/피인용
' Neuroimaging studies for schizophrenia: Brain functional abnormality : Abnormal serotonin transporter binding, glucose metabolism, and interregional correlation in schizophrenia: A dual tracer PET study with 11C-DASB and 18F-FDG' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • glucose metabolism
  • interregional correlation with dual tracer
  • schizophrenia
  • serotonin transporter
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
433 0

0.0%

' Neuroimaging studies for schizophrenia: Brain functional abnormality : Abnormal serotonin transporter binding, glucose metabolism, and interregional correlation in schizophrenia: A dual tracer PET study with 11C-DASB and 18F-FDG' 의 참고문헌

  • Wooley DW, Shaw E. A biological and pharmacological suggestion aboutcertain mentaldisorder.Proc NatlAcad Sci USA.1954;40:228-231.
  • Wode-HelgodtB,Fyro B,Cillberg B,SedvallG.Effectof chlorpromazine treatment on monoamine metabolite levels in cerebrospinalfluidson psychoticpatients.ActaPsychiatrScand. 1977;56:280-293.
  • Winblad B,Bucht C,Cottfries CC,Roos BE.Monoamines and monoamine metabolites in brains from demented schizophrenics.ActaPsychiatrScand.1979;60:17-28.
  • Volkow ND,WolfAP,Van GuelderP,BrodieJD,OverallJE, Cancro R,GomezMF.Phenomenologicalcorrelatesofmetabolic activity in 18 patients with chronic schizophrenia. Am. J. Psychiatry.1987;144(2):151-158.
  • Tzourio-MazoyerN,Landeau B,Papathanassiou D,Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated AnatomicalLabeling ofactivationsin SPM using aMacroscopic AnatomicalParcellation of the MNIMRIsingle-subjectbrain. NeuroImage.2002;15(1):273?289.
  • TammingaCA,ThakerGK,BuchananR,KirpatrickB,Alphs LD, Chase TN, Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocorticalalterations with deficit syndrome.Arch.Gen.Psychiatry.1992;49:522-530.
  • Szechtman H,NahmiasC,GarnettES,FirnauG,Brown GM, Kaplan RD, Cleghorn JM. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry.1988;45:523?532.
  • Szabo Z,Kao PF,ScheffelU,Suehiro M,Mathews WB, RavertHT,Musachio JL,Marenco S,Kim SE,RicaurteGA,et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse.1995;20:37-43.
  • SuehiroM,ScheffelU,DannalsRF,RavertHT,RicaurteGA, Wagner HN Jr. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. J Nucl Med. 1993; 34: 121-127.
  • StrangeBA,FletcherPC,Henson RN,Friston KJ,Dolan RJ. Segregating the functions of human hippocampus. Proc Natl AcadSciUSA.1999;96:4034-4039.
  • Silverthorn ML,DerschCM,BaumannMH,CadetJL,Partilla JS,RiceKC,CarrollFI,BeckettsKM,Brockington A,Rothman RB. Studies of the biogenic amine transporters. V. Demonstration of two binding sites for the cocaine analog [125I]RTI-55 associated with the 5-HT transporterin ratbrain membranes.JPharmacolExpTher.1995;273:213-222.
  • Roth BL and Meltzer HY. The role of Serotonin in Schizophrenia.In:DavisKL,Charney D,CoyleJT,NemeroffC eds. NeuropsychopharmacologyL The Fifth Generation of Progress.5th ed.Philadelphia LippincottWilliams and Wilkins, Philadelphia,USA.2000. SchacterDL,WagnerAD.Medialtemporallobeactivationsin fMRI and PET studies of episodic encoding and retrieval. Hippocampus.1999;9:7-24.
  • OkadaT,FujitaM,ShimadaS,SatoK,SchlossP,Watanabe Y,Itoh Y,Tohyama M,Nishimura T.Assessmentofaffinities of beta-CIT,beta-CIT-FE,and beta-CIT-FP for monoamine transporterspermanently expressedin celllines.NuclMedBiol. 1998;25:53-58.
  • NordahlTE,Kusubov N,Carter C,Salamat S,Cummings AM,O’Shora-Celaya L,Eberling J,Robertson L,Huesman RH, JagustW,BudingerTF.Temporallobemetabolicdifferencesin medication-freeoutpatientswithschizophreniaviathePET-600. Neuropsychopharmacology.1996;15:541-554.
  • Naylor L,Dean B,Opeskin K,Pavey G,HillC,Keks N, Copolov D. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.JNeuralTransm.1996;103:749-757.
  • Naidich TP, Duvernoy HM, Delman BN, Sorensen AG, Kollias SS,HaackeEM.Duvernoy’s Atlas oftheHuman Brain Stem and Cerebellum: High-Field MRI, Surface Anatomy, InternalStructure,Vascularization and 3D SectionalAnatomy. Vienna:Springer;2009. Narr KL,Thompson PM,Szeszko P,Robinson D,Jang S, WoodsRP,Kim S,HayashiKM,Asunction D,TogaAW,Bilder RM,Regionalspecificity of hippocampalvolume reductions in first-episodeschizophrenia.Neuroimage.2004;21:1563-1575.
  • Mita T,Hanada S.Nishino N,Kuno T,NakaiH,Yamadori T,MizoiY,Tanaka C.Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry.1986;21:1407-1414.
  • Malykhin NV,Bouchard TP,OgilvieCJ,Coupland NJ,Seres P, Camicioli R. Three-dimensional volumetric analysis and reconstructionofamygdalaandhippocampalhead,bodyandtail. Psychiatryresearch:Neuroimaging.2007;155:155-165.
  • Lundberg J, Odano I, Olsson H, Halldin C, Farde L. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med. 2005; 46(9): 1505-1515.
  • LepageM,HabibR,Tulving E.HippocampalPET activations of memory encoding and retrieval: the HIPER model. Hippocampus.1998;8:313-322.
  • LehrerDS,Christian BT,MantilJ,Murray AC,Buchsbaum BR, Oakes TR, Byne W, Kemether EM, Buchsbaum MS. Thalamic and Prefrontal FDG Uptake in Never Medicated Patients With Schizophrenia. The American Journal of Psychiatry.2005;162(5):931-938.
  • Laruelle M,Abi-Dargham A,van Dyck E,GilR,D'Souza DC,KrystalJ,SeibylJ,Baldwin R,Innis R.Dopamine and serotomin transporters in patients with schizophrenia: an imaging study with [123I]a-CIT. Biol Psychiatry. 2000; 47: 371-379.
  • Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H]paroxetine binding,a marker of serotonin uptake sites.BiolPsychiatry. 1988;24:299-309.
  • Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontalserotonergicreceptorsin schizophrenia.A postmortem study.ArchGenPsychiatry.1993;50:810-818.
  • Kula NS,BaldessariniRJ,TaraziFI,Fissera R,Wangc S, Trometerd J, Neumeyera JL. [3H]β-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol. 1999;385:291-294.
  • KrystalJH,SeibylJP,Price LH,Woods SW,HeningerGR, Aghajanian GK,Charney DS.m-Ch!orophenylpiperazine effects in neuroleptic-free schizophrenic patients.Evidence implicating serotonergicsystemsin thepositivesymptomsofschizophrenia. ArchCenPsychiahy.1993;50:624-635.
  • Kim JH,Son YD,Kim JH,ChoiEJ,Lee SY,Lee JE,Cho ZH, Kim YB. Serotonin transporter availability in thalamic subregions in schizophrenia: A study using 7.0-T MRI with [(11)C]DASB high-resolutionPET.PsychiatryRes.2015;231(1): 50-57.
  • Kahn RS,SieverU,GabrielS,Amin F,Stern RG,DuMont K,Apter S,Davidson M.Serotonin function in schizophrenia: effects of metachlorophenylpiperazine in schizophrenic patients andhealthysubjects.PsychiatryRes.1992;43:1-12.
  • Joyce JN,Shane A,Lexow N,Winokur A,Casanova MF, Kleinman JE.Serotonin uptakesitesandserotonin receptorsare altered in the limbic system of schizophrenics. Neuropsychopharmacology.1993;8:315-336.
  • IqbalN,AsnisCM,Wetz!erS,Kahn RS,KaySR,van Praag HM.The MCPP challenge testin schizophrenia:hormonaland behavioralresponses.BiolPsychiatry.1991;30:770-778.
  • Hong IK,Chung ST,Kim HK,Kim YB,Son YD,Cho ZH. Ultra fastsymmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE transactionsonnuclearscience.2007;26:789-803.
  • HazlettE,Buchsbaum MS,KemetherE,Bloom R,PlatholiJ, Brickman AM, Shihabuddin L, Tang C, Byne W. Abnormal glucose metabolism in the mediodorsalnucleus ofthe thalamus inSchizophrenia.Am.J.Psychiatry.2004;161:305?314.
  • Gaddum JH. Drug antagonistic to 5-hydroxytryptamine. Boston:WileyOnlineLibrary.1954. Gomes UCR, Shanley Be, Potgieter L, Roux JT. Noradrenergic overactivity in chronic schizophrenia: Evidence based on cerebrospinalfluid noradrenaline and cyclic nucleotide concentrations.BrJPsychiatry.1980;137:346-351.
  • Fujimoto T, Takeuchb K, Matsumotob T, Kamimurab K, Hamadab R, Nakamurab K, Katoa N. Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Research: Neuroimaging. 2007; 154: 49?58.
  • Frankle WG,Slifstein M,Gunn RN,Huang Y,Hwang DR, Darr EA,Narendran R,Laruelle M. Estimation of Serotonin Transporter Parameters with 11C-DASB in Healthy Humans: Reproducibility and Comparison ofMethods.JournalofNuclear Medicine.2006;47(5):815-826.
  • Frankle WG,Narendran R,Huang Y,Hwang DR,Lombardo I,Cangiano C,GilR,Laruelle M,Abi-Dargham A.Serotonin transporter availability in patients with schizophrenia: A positron emission tomography imaging study with [11C]DASB. BiolPsychiat.2005;57:1510-1516.
  • FardeL,Halldin C,MullerL,SuharaT,Karlsson P,HallH. PET study of[11C]β-CIT binding to monoaminetransportersin themonkeyandhumanbrain.Synapse.1994;16:93-103.
  • Dean B,Opeskin K,Pavey G,Naylor L,HillC,Keks N, Copolov DL. [3H]paroxetine binding is altered in the hippocampusbutnotthefrontalcortex orcaudatenucleusfrom subjects with schizophrenia. J Neurochem. 1995; 64(3): 1197-1202.
  • De LisiLE,Buchsbaum MS,Holcomb HH,Langston KC, King AC,Kessler R,Pickar D,Carpenter WJ,Morihisa JM, Margolin R WeinbergerDR.Increasedtemporallobeglucoseuse in chronic schizophrenic patients. Biol. Psychiatry. 1989; 25: 835-851.
  • Crow TJ,Baker HF,Cross AJ,Joseph MH,Lofthouse R, Longden A, Owen F, Riley GJ, Glover V, Killpack WS. Monoamine mechanisms in chronic schizophrenia:post-mortem neurochemicalfindings.BrJPsychiatry.1979;134:249-256.
  • Cleghorn JM,GarnettES,NahmiasC,Firnan G,Brown GM, Kaplan R,Szechtman H,Zsechtman B.Increased frontaland reduced parietal glucose metabolism in acute untreated schizophrenia.Psychiatr.Res.1989;28:119-133.
  • Buchsbaum MS,HazlettEA.Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. SchizophreniaBulleltin.1998;24(3):343-364.
  • Buchsbaum MS,HaierRJ,PotkinSG,NuechterleinK,Bracha HS,KatzM,LohrJ,Wu J,Lottenberg S,Jerabek PA,Trenary M,Taffalla R,ReynoldsC,Bunney WE.Frontostriataldisorder ofcerebralmetabolism in never-medicated schizophrenics.Arch GenPsychiatry.1992;49:935-942.
  • Buchsbaum MS, Ingvar DH, Kessler R, Waters RN, CappellettiJ,Kammen DP,King AC,Johnson JL,Manning RG, Flynn RW, Mann LS, Bunney WE, Sokoloff L. Cerebral glucography with positron tomography;use in normalsubjects andin patientswith schizophrenia.Arch.Gen.Psychiatry.1982; 39:251-259.
  • BrustP,Hesse S,MullerU,Szabo Z.Neuroimaging ofthe Serotonin Transporter ? Possibilities and Pitfalls. Current PsychiatryReview.2006;2:111-149.
  • BowersMB Jr.HeningerCR,GerbodeF.Cerebrospinalfluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients.InternationalJournalof Neuropharmacology.1969;8: 255-262.
  • Boja JW,McNeillRM,Lewin AH,Abraham P,CarrollFI, Kuhar MJ. Selective dopamine transporter inhibitation by cocaineanalogs.Neuroreport.1992;3:984-986.
  • Backstrom I, Bergstrom M, Marcusson J. High affinity [3H]paroxetinebindingtoserotoninuptakesitesinhumanbrain tissue.BrainRes.1989;486:261-268.
  • Ashcroft CW,Crawford TBB, Eccleston D, Sharman DF, Macdougall EJ, Stanton JB, Binns JK. 5-Hydroxyindole compoundsinthecerebrospinalfluidofpatientswithpsychiatric orneurologicaldiseases.Lancet.1966;2:1049-1052.
  • Arora RC,MeltzerHY.Serotonin2 (5-HT.,)receptorbinding in frontalcortex of schizophrenic patients.J NeuralTransm. 1991;85:19-29.